Medocriptine (Bromocriptine)

Bromocriptine acts as an agonist at dopamine D2 receptors, suppressing prolactin release from the pituitary and stimulating dopaminergic pathways in the brain, which together improve motor function and metabolic regulation.

The appropriate dose of Medocriptine is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage regimens are not standardized and should follow the prescriber's instructions.

Safety data for bromocriptine in pregnancy and lactation are limited. It should only be used if the potential benefits justify any possible risks to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Medocriptine, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑ergot dopamine agonists, bromocriptine has a longer history of use and distinct receptor binding characteristics. It may be preferred for its efficacy in hyperprolactinemia and its metabolic benefits in type 2 diabetes, but it also carries a higher risk of ergot‑related vascular side effects.

Medocriptine tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Medocriptine is taken orally, usually with a glass of water. The exact timing (e.g., with meals or on an empty stomach) and frequency are determined by the prescribing physician based on the therapeutic indication.

Serious risks include valvular heart disease, pulmonary fibrosis, severe hypotension, psychotic reactions, seizures, and hepatic dysfunction. Patients should be monitored regularly for cardiovascular and neurological symptoms, especially during the early phases of therapy.

Medocriptine is contraindicated in patients with known hypersensitivity to bromocriptine or other ergot derivatives, uncontrolled hypertension, active cardiac valvulopathy, or a history of severe hepatic impairment. It should also be avoided in individuals taking contraindicated ergot medications.